araag2/HINT huggingface dataset:
Clinical trial NCT00904423 (phase 1/phase 2, status: terminated)
Conditions: breast cancer, bone diseases
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60, M83.4, H05.321, H05.322, H05.323, H05.329
Drugs: vitamin d
SMILES: CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C
Reason stopped: 
    low accrual
  
Eligibility criteria:

        Inclusion Criteria:

        3.1.1 All postmenopausal women with histology-confirmed invasive primary breast cancer, who
        have completed primary surgical or radiotherapy (XRT) with or without adjuvant chemotherapy
        and are candidates to receive adjuvant therapy with aromatase inhibitors will be screened
        for eligibility. Postmenopausal is defined as satisfying one or more of the following
        criteria: having had bilateral oophorectomy; aged more than 60 years; or aged 55-59 years
        with an intact uterus and amenorrheic for at least 12 months; or if amenorrheic for less
        than 12 months (after receiving hysterectomy, hormone therapy or chemotherapy).

        3.1.2 At the time of study enrollment, participants will have completed primary surgical or
        XRT with or without adjuvant chemotherapy. Chemotherapy will be completed at least 28 days
        prior to enrollment.

        3.1.4 Participants will be women between 18-85 years of age. Women and minorities will be
        actively recruited. Though breast cancer extremely rarely occurs in children and men, this
        study will only recruit adult females.

        3.1.5 Participants will have a life expectancy of at least 5 years.

        3.1.6 Participants will have Eastern Clinical Oncology Group (ECOG) performance status 0-2.

        3.1.7 Ability to understand and the willingness to sign a written informed consent document

        Exclusion Criteria:

        3.2.1 Medications affecting bone metabolism (bisphosphonates, anticonvulsants, chronic
        heparin therapy, chronic glucocorticoid use > 5 mg/day prednisone or equivalent,
        teriparatide).

        3.2.2 Use of any investigational drug within past 90 days.

        3.2.3 Metastatic breast cancer. High risk for osteoporosis/fractures (BMD < -2.0, history
        of non-traumatic fracture). Hyperparathyroidism Hypercalcemia Hypercalciuria (fasting spot
        urine calcium/creatinine ratio >0.20) History of renal stones Renal failure with creatinine
        over 2.0

        3.2.4 Considering that vitamin D3 is produced by the human body, allergy to vitamin D3 is
        not expected to develop. Subjects with known history of allergic reaction to compounds used
        to manufacture capsules (rice powder) will be excluded form this study.

        3.2.5 Recent history of excessive alcohol or drug use.

        3.2.6 As this study will recruit post-menopausal patients, thus pregnant or nursing
        patients are not part of this investigation.

        3.2.8 This study is designed to study women after completing primary therapy for breast
        cancer. Survivors of previous cancers and HIV-positive subjects will not be excluded.
Clinical trial NCT01133912 (phase 1, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: paclitaxel, gemcitabine, lapatinib
SMILES: NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed and newly diagnosed operable breast cancer

          -  Documented HER2 positive disease : 3+ overexpression by IHC or HER2 gene amplification
             by FISH

          -  ECOG performance status 0-2

          -  Age ≥ 18 years

          -  Clinical stage II or III operable breast cancer

          -  Axillary node positivity determined by cytology

          -  No prior hormonal, chemotherapy, or radiotherapy is allowed

          -  No breast operation other than biopsy to make diagnosis is allowed

          -  Negative urine pregnancy test within 7 days prior to registration in premenopausal
             patients

          -  Adequate hematopoietic function: Absolute granulocyte count ≥1,500/mm3, platelet
             ≥100,000/mm3, hemoglobin ≥10g/mm3

          -  Adequate hepatic function: total bilirubin ≤1.5mg/dL, AST/ALT ≤2 x UNL, alkaline
             phosphatase ≤2 x UNL

          -  Adequate renal function: Serum creatinine ≤1.5mg/dL

          -  Adequate cardiac function:

               1. Normal or nonspecific EKG taken within 1 month of enrollment

               2. LVEF ≥50% by MUGA or echocardiogram taken within 4 weeks of enrollment

          -  Ability to understand and comply with protocol during study period

          -  Patients should sign a written informed consent before study entry

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  Patients who received hormonal, chemotherapy or radiotherapy for breast cancer

          -  Patients with bilateral breast cancer

          -  Patients who underwent surgery for breast cancer

          -  Patients with node-negative stage IIA (T2N0) breast cancer

          -  Patients who have history of cancer other than in situ uterine cervix cancer or
             nonmelanotic skin cancer

          -  Patients with GI tract disease resulting in an inability to take oral medication,
             malabsorption syndrome, a requirement for IV alimentation, prior surgical procedures
             affecting absorption, uncontrolled GI disease (e.g., Crohn's disease, ulcerative
             colitis)
Clinical trial NCT01867866 (phase 1, status: completed)
Conditions: advanced solid tumors
ICD codes: K74.02, G47.22, H35.3133, H35.3134, H35.3113, H35.3114, H35.3123
Drugs: tas-102, trifluridine
SMILES: ClC1=C(CN2CCCC2=N)NC(=O)NC1=O, OC[C@H]1O[C@H](C[C@@H]1O)N1C=C(C(=O)NC1=O)C(F)(F)F
Eligibility criteria:

        Inclusion Criteria:

          1. Has provided written informed consent

          2. Has advanced solid tumors (excluding breast cancer) for which no standard therapy
             exists

          3. ECOG performance status of 0 or 1

          4. Is able to take medications orally

          5. Has adequate organ function (bone marrow, kidney and liver)

          6. Women of childbearing potential must have a negative pregnancy test and must agree to
             adequate birth control if conception is possible. Males must agree to adequate birth
             control.

        Exclusion Criteria:

          1. Has had certain other recent treatment e.g. anticancer therapy, received
             investigational agent, within the specified time frames prior to study drug
             administration

          2. Certain serious illnesses or medical condition(s)

          3. Has had either partial or total gastrectomy

          4. Has unresolved toxicity of greater than or equal to CTCAE Grade 2 attributed to any
             prior therapies

          5. Known sensitivity to TAS-102 or its components

          6. Is a pregnant or lactating female

          7. Refuses to use an adequate means of contraception (including male patients)
Clinical trial NCT00279240 (phase 1, status: completed)
Conditions: diabetes
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65
Drugs: metformin
SMILES: CSCC[C@H](N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Both male and female. 35 - 55 years. No Known history of diabetes. Willing and
             available for a three years study.

        Exclusion Criteria:

          -  Pregnant women. Subjects with major illness such as cancer, hepatic or cardiac
             diseases. Tranferable jobs.
Clinical trial NCT00618527 (early phase 1, status: completed)
Conditions: multiple sclerosis
ICD codes: G35, C81.18
Drugs: mycophenolate mofetil (cellcept), human interferon beta 1a (rebif)
SMILES: COC1=C(C\C=C(/C)CCC(=O)OCCN2CCOCC2)C(O)=C2C(=O)OCC2=C1C, CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1
Eligibility criteria:

        Inclusion Criteria:

          -  diagnosed with relapsing remitting multiple sclerosis

          -  eligible to initiate interferon therapy

          -  between he ages of 18-65, inclusive

        Exclusion Criteria:

          -  have received corticosteroids within 30 days prior to study start

          -  have ever received cyclophosphamide or mitoxantrone

          -  have received Imuran or methotrexate in the last 3 months

          -  females that are pregnant or breastfeeding are excluded
Clinical trial NCT00389285 (phase 1/phase 2, status: completed)
Conditions: carcinoma, renal cell
ICD codes: C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8
Drugs: ril-21 only, ril-21 + sorafenib
SMILES: CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of RCC of predominantly clear cell histology

          -  Either no prior treatment or a maximum of 2 prior treatment regimens for metastatic
             RCC that included no more than 1 treatment regimen targeting the vascular endothelial
             growth factor (VEGF) pathway (Phase 1 only)

          -  At least 1 but no more than 2 prior systemic therapies for metastatic RCC that
             included no more than 1 therapy targeting the VEGF pathway (Phase 2 only)

          -  Disease measurable per the Response Evaluation Criteria in Solid Tumors (RECIST)
             (Phase 2 only)

        Exclusion Criteria:

          -  Presence of acute infection or other significant systemic illness

          -  Central nervous system involvement by malignancy

          -  History of other cancer within 5 years

          -  Previously received rIL-21 or sorafenib
Clinical trial NCT00598923 (early phase 1, status: terminated)
Conditions: traumatic brain injury, epilepsy
ICD codes: Z87.820, Z13.850, S06.2X0S, S06.2X0A, S06.2X0D, S06.300S, S06.300A, G40.803, G40.804, G40.911, G40.919, G40.B11, G40.B19, G40.801
Drugs: topiramate, topiramate, phenytoin
SMILES: [H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2, [H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2, OC(=O)C1=CC=CC=C1O
Reason stopped: 
    end of funding and low enrollment
  
Eligibility criteria:

        Inclusion Criteria:

          1. Moderate to severe traumatic brain injury, defined as one or more of the following:
             penetrating head wound seizure within the first hour after injury intracerebral
             hematoma or cortical contusion subdural or epidural hematoma Glasgow Coma Score <= 12
             or motor score 1-5 (if intubated). Patients who have been pharmacologically paralyzed
             will be evaluated after the paralytic has worn off or been pharmacologically reversed
             depressed skull fracture requirement for emergent neurosurgical procedure

          2. Time since TBI less than 24 hours

          3. Age greater than or equal to 18 years

          4. Subject capable of giving informed consent or have an acceptable surrogate capable of
             giving consent on the subject's behalf. -

        Exclusion Criteria:

          1. Known prior history of epilepsy or unprovoked seizures. Patients with a history of
             acute symptomatic seizures (e.g. febrile seizure, alcohol withdrawal seizure) will not
             be excluded

          2. Administration of an antiepileptic drug before enrollment

          3. History of allergy to topiramate or phenytoin

          4. Pregnancy or breast-feeding. Women of childbearing potential must have a negative
             pregnancy test (urine pregnancy test or serum beta-HCG) before randomization

          5. Compromised renal function with serum creatinine > 2

          6. Severe concurrent illness with life expectancy <6 months

          7. Treatment with another investigational agent for TBI

          8. Unable to take medications orally and contraindication to placement of nasogastric
             tube.

          9. Irreversibly fatal TBI

               1. All four findings: Glasgow Coma Score = 3, no pupillary reaction, age > 45 years,
                  and severe coagulopathy OR

               2. Severe brainstem lesion on neuroimaging studies

         10. Patients with a history of kidney stones or glaucoma.

         11. Inability to maintain adequate fluid intake while taking topiramate.

         12. Patients whose TBI is a result of self inflicted injury

         13. Patient's who are currently using illicit drugs -
Clinical trial NCT00256334 (phase 1, status: completed)
Conditions: colon cancer, cancer
ICD codes: C18.2, C18.4, C18.6, C18.7, C18.9, D12.2, D12.3, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: resveratrol
SMILES: OC1=CC=C(\C=C\C2=CC(O)=CC(O)=C2)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients diagnosed with colon cancer by colonoscopic biopsy and tissue obtained under
             UCI04-05.

          -  Patients with a plan for surgical resection at UCIMC within 2-4 weeks of enrollment.

        Exclusion Criteria:

          -  Surgical resection to be performed at a facility other than UCIMC.

          -  Patients under 18 years of age.
Clinical trial NCT01227239 (phase 1/phase 2, status: unknown status)
Conditions: rectal carcinoma
ICD codes: C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31
Drugs: s-1, oxaliplatin
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          1. Patients with confirmed locally advanced and non-metastatic rectal adenocarcinoma
             (clinical stage T3, anyN or T4, anyN)

          2. Possible to R0 resection

          3. Received no prior therapy

          4. Performance status (ECOG) 0-1

          5. Normal organ and marrow function.

          6. Sufficient oral intake

        Exclusion Criteria:

          1. History of serious allergic reaction

          2. Patients without serious complications such as sensory neurotoxicity or serious
             diarrhea (with watery stool).

          3. Female with pregnancy or lactation

          4. Have another malignancy in the past 5 years except early stage other cancer that cure
             by local treatment
Clinical trial NCT00329004 (phase 1, status: completed)
Conditions: cancer, tumor
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, E88.3, R97.8, C49.A0, C49.A1, C49.A2, C49.A5, C49.A3
Drugs: bms-690514
SMILES: COC1=CC=CC(NC2=NC=NN3C=CC(CN4CC[C@@H](N)[C@H](O)C4)=C23)=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Men and women 18 and older

          -  Diagnosis of any solid tumor

          -  ECOG performance status score 0-1

          -  Prior chemo-therapy, immunotherapy or radiotherapy with at least 4 weeks since the
             last treatment

          -  Treatment with VEGFR2 or HER1 TKI allowed but not both (for instance Avastin or
             Tarceva, but not both)

        Exclusion Criteria:

          -  Treatment with other TKIs within the past 4 weeks

          -  Patients with brain metastasis

          -  Patients with centrally located squamous cell carcinoma of the lung

          -  Major gastrointestinal surgery which may affect absorption of the drug

          -  Any surgery within last 4 weeks

          -  History of thromboembolism

          -  Severe unmanageable diarrhea

          -  Subjects in Part B will have Non-Small Cell Lung Cancer (NSCLC)

          -  Part B/Cohort I erlotinib-naive subjects

          -  Part B/Cohort II subjects who have experienced disease progression while receiving
             erlotinib (erlotinib-resistant subjects)
Clinical trial NCT01107899 (phase 1, status: terminated)
Conditions: acute coronary syndromes
ICD codes: I24.0
Drugs: clopidogrel, prasugrel
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, CC(=O)OC1=CC2=C(CCN(C2)C(C(=O)C2CC2)C2=CC=CC=C2F)S1
Reason stopped: 
    terminated due to enrollment futility
  
Eligibility criteria:

        Inclusion Criteria:

          -  Men or women ≥18 to <80 years of age who present with any one of the following:

          -  symptoms of Acute Coronary Syndromes (ACS)

          -  clinical symptoms of angina, or a positive stress test or who return for routine
             follow up angiography post stent placement in whom co-administration of aspirin and a
             thienopyridine (that is, clopidogrel, ticlopidine, or prasugrel) is not
             contraindicated

        Exclusion Criteria:

          -  Those presenting with ST-elevation MI (STEMI)

          -  histories of refractory ventricular arrhythmias

          -  an implanted defibrillator device

          -  congestive heart failure (NYHA Class III or above) within 6 months prior to screening

          -  significant hypertension

          -  subjects with a history or clinical suspicion of cerebral vascular malformations,
             transient ischaemic attack, or stroke

          -  bleeding disorders

          -  women known to be pregnant, who have given birth within the past 90 days, or who are
             breastfeeding
Clinical trial NCT01463982 (phase 1, status: completed)
Conditions: solid tumor, advanced cancer
ICD codes: K74.02, G47.22, H35.3133, H35.3134, H35.3113, H35.3114, H35.3123
Drugs: oratecan and capecitabine
SMILES: CCCCCOC(=O)NC1=NC(=O)N(C=C1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed advanced solid tumor

          -  Patients who have experienced progressive disease despite of conventional anticancer
             therapy. Patients who cannot expect effective treatment or prolonged survival with
             conventional anticancer therapy

          -  Previous chemotherapy, radiotherapy and surgical operation are allowed if they are
             discontinued for at least 4 weeks prior to D0 and all adverse events are resolved

          -  Aged ≥19

          -  Eastern Cooperative Oncology Group (ECOG) performance score of less than or equal to 2

          -  A life expectancy greater than 12 weeks

          -  Adequate bone marrow, renal and liver function.

          -  Subjects must provide written informed consent prior to performance of study specific
             procedures or assessments, and must be willing to comply with treatment and follow up
             assessments and procedures

        Exclusion Criteria:

          -  Patients with hematopoietic malignancies,uncontrolled infection, CNS metastasis.

          -  Patients who have undergone hematopoietic stem cell transplantation (HSCT) or are
             candidates for planned HSCT

          -  Patients who have GI malabsorption or difficulty taking oral medication

          -  Patients who have psychiatric or congenital disorder Subjects who, in the
             investigator's opinion, cannot be treated per protocol due to functional impairments

          -  Pregnant or breast-feeding patients; Women of childbearing potential without adequate
             contraception (Men must use adequate contraception.)
Clinical trial NCT01028781 (phase 1, status: terminated)
Conditions: endometriosis
ICD codes: N80.8, N80.9, N80.0, N80.1, N80.5, N80.2, N80.3
Drugs: thalidomide
SMILES: CC(C)NCC(O)COC1=CC=CC2=C1C=CC=C2
Reason stopped: 
    difficulty finding eligible participants and lack of funding.
  
Eligibility criteria:

        Inclusion Criteria:

          1. Age > 18 years

          2. Histologically/laparoscopically confirmed endometriosis

          3. Chronic pelvic pain defined as non-menstrual pain for at least two weeks in the
             previous month for at least 6 months

          4. VAS of 6 or more at baseline

          5. Failure, completion or intolerance of standard treatment modalities (oral
             contraceptive therapy, danazol, Depo-Provera, Depo-Lupron)

          6. Patients must give written informed consent.

          7. Patients must be willing and able to comply with the FDA-mandated S.T.E.P.S.® program.

        Exclusion Criteria:

          1. Pregnant and/or lactating female

          2. Users of other angiogenesis inhibitors

          3. Current use of Rifampin, rifabutin, barbiturates, glucocorticoids, phenytoin,
             carbamazepine, chlorpromazine, reserpine, penicillin derivatives, or St. Johns Wart in
             user of oral contraceptive therapy

          4. Use of aromatase inhibitors, Etanercept (Enbrel), GnRH agonists (Depo-Lupron), and
             Danazol within the past 3 months

          5. Use of norethindrone acetate (Aygestin) in the prior month

          6. Seizure disorder

          7. Hepatitis, or any active infection (upper respiratory infection, PID, etc)

          8. History of thromboembolic disease.

          9. Baseline neutropenia (ANC < 1000/mm^3)

         10. Any severe physical or metal illness that would interfere with the completion of the
             protocol

         11. Illicit drug or alcohol abuse
Clinical trial NCT00463697 (phase 1, status: completed)
Conditions: pulmonary disease, chronic obstructive
ICD codes: J44.9, J44.1, J44.0
Drugs: gw642444h (100mcg), placebo, gw642444m (25, 100 & 400 mcg)
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, OCC1=C(O)C=CC(=C1)[C@@H](O)CNCCCCCCOCCOCC1=C(Cl)C=CC=C1Cl
Eligibility criteria:

        Inclusion criteria:

          -  male or female (of non-childbearing potential) between 18 - 70 years

          -  History of stable mild to moderate asthma

          -  non - smokers

          -  currently taking daily doses of inhaled fluticasone propionate 200 - 500 mcg (or
             equivalent)

          -  body weight >50 kg with BMI 19-29.9 kg/m2

          -  normal ECG assessment

        Exclusion criteria:

          -  history of significant disease

          -  history of life threatening asthma

          -  recent respiratory tract infection

          -  recent change of asthma medication

          -  treatment with high dose inhaled corticosteroids or oral corticosteroids

          -  recent participation in another trial

          -  history of drug or alcohol abuse

          -  known allergies (excluding asthma)

          -  recent blood donation